Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

AdaptHealth (AHCO) EBITDA (2018 - 2025)

AdaptHealth (AHCO) has 8 years of EBITDA data on record, last reported at $19.2 million in Q4 2025.

  • For Q4 2025, EBITDA fell 89.48% year-over-year to $19.2 million; the TTM value through Dec 2025 reached $452.5 million, down 25.44%, while the annual FY2025 figure was $452.5 million, 25.44% down from the prior year.
  • EBITDA reached $19.2 million in Q4 2025 per AHCO's latest filing, down from $154.4 million in the prior quarter.
  • Across five years, EBITDA topped out at $182.7 million in Q4 2024 and bottomed at -$370.7 million in Q3 2023.
  • Average EBITDA over 5 years is $87.5 million, with a median of $131.3 million recorded in 2021.
  • Peak YoY movement for EBITDA: surged 921.27% in 2021, then tumbled 373.91% in 2023.
  • A 5-year view of EBITDA shows it stood at $134.1 million in 2021, then dropped by 11.22% to $119.0 million in 2022, then crashed by 210.06% to -$131.0 million in 2023, then surged by 239.44% to $182.7 million in 2024, then crashed by 89.48% to $19.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA were $19.2 million in Q4 2025, $154.4 million in Q3 2025, and $166.5 million in Q2 2025.